Oak Ridge Investments LLC Sells 632 Shares of Guardant Health, Inc. (NASDAQ:GH)

Oak Ridge Investments LLC trimmed its holdings in Guardant Health, Inc. (NASDAQ:GH) by 3.9% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 15,552 shares of the company’s stock after selling 632 shares during the quarter. Oak Ridge Investments LLC’s holdings in Guardant Health were worth $357,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Quarry LP purchased a new position in shares of Guardant Health in the second quarter worth $44,000. Manchester Capital Management LLC purchased a new position in Guardant Health during the 1st quarter valued at $57,000. Canton Hathaway LLC purchased a new position in Guardant Health during the 2nd quarter valued at $59,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Guardant Health during the 2nd quarter valued at $71,000. Finally, EntryPoint Capital LLC purchased a new position in Guardant Health during the 1st quarter valued at $75,000. 92.60% of the stock is currently owned by institutional investors.

Guardant Health Price Performance

NASDAQ GH opened at $23.00 on Friday. Guardant Health, Inc. has a 12 month low of $15.81 and a 12 month high of $37.04. The stock has a market cap of $2.83 billion, a price-to-earnings ratio of -5.62 and a beta of 1.11. The company’s 50 day moving average is $23.27 and its two-hundred day moving average is $25.61. The company has a current ratio of 6.40, a quick ratio of 6.07 and a debt-to-equity ratio of 16.70.

Guardant Health (NASDAQ:GH) last released its earnings results on Wednesday, August 7th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.10). The firm had revenue of $177.24 million for the quarter, compared to the consensus estimate of $162.59 million. Guardant Health had a negative return on equity of 418.21% and a negative net margin of 76.23%. Guardant Health’s revenue was up 29.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.67) EPS. As a group, research analysts anticipate that Guardant Health, Inc. will post -3.31 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Bank of America boosted their target price on shares of Guardant Health from $28.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, July 18th. UBS Group upped their price target on shares of Guardant Health from $32.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, August 21st. Piper Sandler upped their price target on shares of Guardant Health from $30.00 to $34.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 13th. BTIG Research upped their price target on shares of Guardant Health from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, July 30th. Finally, The Goldman Sachs Group upped their price target on shares of Guardant Health from $28.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, July 17th. One analyst has rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat, Guardant Health presently has an average rating of “Moderate Buy” and an average price target of $40.00.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.